trial 1,940 words KG: GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy
Contents

GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

Wikipedia

Related Hypotheses (14)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.38
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
TREM2-mediated microglial tau clearance enhancement
Score: 0.62
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.48
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam
Score: 0.79
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
APOE-TREM2 Interaction Modulation
Score: 0.74
Phase-Separated Organelle Targeting
Score: 0.73
Stress Granule Phase Separation Modulators
Score: 0.72
Vagal Afferent Microbial Signal Modulation
Score: 0.62
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58
TREM2-Dependent Microglial Senescence Transition
Score: 0.58
Vocal Cord Neuroplasticity Stimulation
Score: 0.52

Related Analyses (11)

Neuroinflammation and microglial priming in early Alzheimer'
neurodegeneration · archived
Extracellular vesicle biomarkers for early AD detection
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Synaptic pruning by microglia in early AD
neurodegeneration · archived

Related Experiments (11)

ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
TLR expression analysis in Parkinson's disease patients
clinical · proposed · Score: 0.85
TLR4 Activation Assay with NETs and Anti-CarP Antibodies
exploratory · proposed · Score: 0.85
TLR expression in α-synuclein overexpressing mice
validation · proposed · Score: 0.80

Knowledge Graph (3 edges)

GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy references BDNF
GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy references TLR4
GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy references TREM2

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.